Application of the human hepatitis B virus core antigen from transgenic tobacco plants for serological diagnosis
Related Experiment Video
Updated: Oct 29, 2026
A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
Published on: May 10, 2022
S Tsuda1, K Yoshioka, T Tanaka
1Plant Biotechnology Institute, Ibaraki Agricultural Center, Iwama, Japan. stsuda@mxj.meshnet.or.jp
Background And Objectives:
The aim was to produce HBcAg from plants more cheaply than can be done by other currently available means, and to apply such antigen to immunoassay procedures for pretransfusion testing of donor blood.
Materials And Methods:
Transgenic Nicotiana tabacum cv. SR-1 plants expressing the human hepatitis B virus (HBV) core antigen (HBcAg) gene were generated by Agrobacterium-mediated transformation. The recombinant product, called tHBcAg, can assemble itself into a spherical particle with a diameter of 25 to 30 nm, and can maintain two antigenic determinants of HBcAg, namely HBc/alpha and HBc/beta. Partly purified tHBcAg was used in the hemagglutination-inhibition (HI) test, as routinely used by the Japanese Blood Center, to test a panel of 524 blood units taken from HBV-positive donors.
Results:
In the HI test, tHBcAg showed serologic properties comparable to that from Escherichia coli, the standard antigen used in the Japanese Blood Center.
Conclusions:
Transgenic plants can produce reagents for serologic testing and perhaps even such medical materials as oral vaccines.
Related Concept Videos
02:50Transgenic Plants
The first-ever transgenic plant was a tobacco plant developed in 1983 that showed resistance against the tobacco mosaic virus. Since then, many transgenic plants have been developed and commercialized for improving the agricultural, ornamental, and horticultural value of a crop plant. Transgenic...
01:26Transgenic Organisms